Results 251 to 260 of about 273,161 (350)

Considerations for Menstrual Suppression in Patients With Hematologic Malignancies

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.
ABSTRACT Patients who menstruate during treatment for hematologic malignancies have a higher risk of heavy vaginal bleeding due to thrombocytopenia caused by malignancy and myelosuppressive chemotherapy. Heavy menstrual bleeding is associated with significant morbidity in this patient population, and menstrual suppression is a standard of supportive ...
Sahaana Veeravalli, Allison Schepers, Lydia L. Benitez, Martina S. Fraga   +3 more
wiley   +1 more source

A Retrospective Analysis of the Clinicopathological Spectrum and Survival Outcome of Non-Hodgkin Lymphoma From a Tertiary Care Hospital in Saudi Arabia. [PDF]

Cureus
Mahmood N, Aamir S, Alseraye A, Alammari A, Alyahya A, Alammari K, Alahmari S.   +6 more
europepmc   +1 more source

Overall Good Quality of Life Reported by Survivors of Childhood Hodgkin Lymphoma in Sweden and Finland

Acta Paediatrica, Volume 115, Issue 3, Page 697-705, March 2026.
ABSTRACT Aim Most children with Hodgkin lymphoma (HL) survive today, yet about 50% experience long‐term complications. This study evaluated health‐related quality of life (HRQoL) in survivors of childhood HL. Methods Two different HRQoL‐instruments, the EuroQoL 5‐Dimension 5‐Level (EQ‐5D‐5L) and Patient‐Reported Outcomes Measurement Information System (
Mia Giertz, Annika Englund, Fanny Fernsten, Sascha Michelsen Wilk, Riitta Niinimäki, Arja Harila, Henri Aarnivala   +6 more
wiley   +1 more source

Predictive value of the serum albumin change rate for therapeutic response to targeted therapy in patients with AIDS-related non-Hodgkin lymphoma. [PDF]

Front Nutr
Xingzhen C, Jing Y, Tingyu C, Yong Z, Guo W.   +4 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Immunosenescence phenotypes and prognostic significance of CD8 + CD28- T cells in AIDS-related non-Hodgkin lymphoma. [PDF]

Ann Med
Kang Z, Tao X, Wu S, Chu S, Peng J, Chen J.   +5 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Blood
Sam J, Leclercq-Cohen G, Gebhardt S, Surowka M, Herter S, Lechner K, Relf J, Briner S, Varol A, Appelt B, Domocos I, Nicolini V, Bez M, Bommer E, Jenni S, Schoenle A, Le Clech M, Colombetti S, Klein C, Umaña P, Lundberg P, Korfi K, Bottos A, Bacac M.   +23 more
europepmc   +1 more source

Economic burden and quality of life caused by non-hodgkin lymphoma cancer in Iran. [PDF]

J Health Popul Nutr
Ghiasi M, Nikbakht HA, Tajik A, Ghavami V, Salek R, Darabi M, Mohammadnabizadeh S, Mojtabaeian SM, Sharifi F, Varmaghani M.   +9 more
europepmc   +1 more source

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source